Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabspace Reports Positive Data from Phase I Trial of 2nd-Gen PDL1

publication date: May 28, 2020

Mabspace Biosciences (Suzhou) reported positive results from a Phase I trial of its PDL1 targeting antibody in pre-treated patients with advanced solid tumors and hematological malignancies. Among the solid tumor group, patients who received the highest dose had an overall response rate of 33% (4/12), with three of the four responses lasting to data cutoff. Mabspace described MSB2311 as a second generation PD-L1 antibody that is the first in its class to have an pH-dependent antigen binding property. Mabspace is a subsidiary of China biopharma Transcenta Holding. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here